Login to get immediate access to this content.
LoginSpeaker: Komal Jhaveri, USA
Abstracts discussed:
- 182MO - Trastuzumab deruxtecan (T-DXd) vs Treatment of Physician’s Choice in HER2+ mBC: Watch the presentation from ESMO Breast 2024 now
- LBA2: Datopotamab deruxtecan (Dato-DXd) vs chemotherapy (CT) in pretreated, inoperable/metastatic HR+/HER2– breast cancer (BC): Additional safety analysis from TROPION-Breast01: View the abstract from ESMO Breast 2024
The speakers and studies featured in this video series were selected independently by ESMO.
Published July 2024